UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
sales of 3.12 billion Euros [US$3.79 billion]
(2.69 billion Euros [US$3.27 billion]
Lonza Group AG
based in SWITZERLAND
(4.51 billion Swiss Francs [US$4.97 billion]
UCB Sa reported sales of 5.35 billion Euro (US$6.50 billion)
December of 2020.
increase of 8.8%
versus 2019, when the company's sales were 4.91 billion Euro.
Sales at UCB Sa have increased during each of the previous five years
(and since 2015, sales have increased a total of 38%).